phone Contact Us

Business Updates

Opharmic Selected as Winner of the 2021 APAC MedTech Innovator Competition

Opharmic Selected as Winner of the 2021 APAC MedTech Innovator Competition

Hong Kong, 20 October 2021

Opharmic Wins 2021 APAC MedTech Innovator Competition

Opharmic Technology (HK) Limited is thrilled to announce that it has been selected as the Grand Prize Winner of the 2021 APAC MedTech Innovator Competition. This prestigious regional award recognizes the most promising and innovative medical technology companies across Asia-Pacific.

The competition, which attracts top medtech startups and scale-ups, evaluates participants on scientific merit, clinical impact, market potential, and execution capability. Opharmic stood out for its groundbreaking non-invasive ultrasound platform that addresses critical challenges in drug delivery.

MeticTouch®, Opharmic’s flagship platform for ocular drug delivery, uses novel ultrasound technology to temporarily and safely enhance the permeability of ocular tissues, enabling effective non-invasive drug delivery for retinal disease management.

Winning this award validates the strength of Opharmic’s technology and the dedication of its team. Starting as a university spin-off to now an established startup, the company has consistently demonstrated its ability to translate cutting-edge research into practical, patient-centric solutions.

“This recognition from the APAC MedTech Innovator Competition is a tremendous honor and a strong endorsement of our approach,” said Sarah Cheung, COO of Opharmic Technology. “It motivates us to accelerate our development timeline and pursue strategic partnerships that will bring these transformative technologies to patients faster.”

The win provides Opharmic with valuable visibility among investors, potential collaborators, and industry leaders across the region. It also reinforces Hong Kong’s position as a growing hub for medtech innovation.

Looking forward, Opharmic plans to leverage this momentum to advance its technology optimization, product development, and regulatory planning, and strengthen its pipeline toward clinical trials. The company remains committed to developing safe, effective, and accessible solutions that improve quality of life in ophthalmology and other therapeutic areas.

Author

Opharmic Technology